SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study

Sponsor
Yonsei University
Study ID
NCT07198191
Status
Active Not Recruiting

Conditions

  • Acute Myocardial Infarction (AMI)
  • Type 2 Diabetes Mellitus (T2DM)

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This observational, retrospective cohort study aims to evaluate the impact of sodium-glucose cotransporter 2 (SGLT2) inhibitor use after acute myocardial infarction (AMI) in patients with type 2 diabetes mellitus (T2DM). Using the nationwide database from the Korean National Health Insurance Service, the investigators will compare cardiovascular outcomes between patients treated with SGLT2 inhibitors and those treated with dipeptidyl peptidase-4 (DPP4) inhibitors after AMI. The study period includes patients diagnosed with AMI between September 2014 and June 2021, with follow-up data available through June 2022. The primary outcomes include major cardiovascular events (death, myocardial infarction, stroke) and bleeding events. This study will provide real-world evidence on the effectiveness and safety of SGLT2 inhibitors in routine clinical practice following AMI among patients with T2DM in Korea.

Key Dates

Start date
Sep 1, 2014
Status verified
Sep 2025
Primary completion
Jun 30, 2022
Completion
Aug 30, 2026

Study Design

Enrollment
200,000 participants (estimated)

Arms

  • Arm: SGLT2 Inhibitor Group
    Patients with type 2 diabetes mellitus (T2DM) who were prescribed SGLT2 inhibitors after acute myocardial infarction.
  • Arm: DPP4 Inhibitor Group
    Patients with type 2 diabetes mellitus (T2DM) who were prescribed DPP4 inhibitors after acute myocardial infarction.

Primary Outcome Measure

Incidence of Major Adverse Cardiovascular Events (MACE) [ Time Frame: From index date (hospitalization for AMI), upto 365 days ]

Related Studies